



October 1, 2020
Reborna Biosciences, Inc.

Notice Regarding the Appointment of Mr. Yasushi Shingai as an Advisor

Reborna Biosciences, Inc. (hereinafter "Reborna" or "the Company") announced today the appointment of Mr. Yasushi Shingai (former Executive Vice President and Deputy CEO of Japan Tobacco Inc.) as an Advisor, effective October 1, 2020.

Reborna's mission is to develop treatments for patients suffering from rare genetic diseases, allowing the patients and their families to feel like they have been reborn, and we are constantly conducting innovative drug discovery research. In welcoming Mr. Shingai as an advisor, we are confident that he will be able to utilize his many years of expertise in corporate management and business development to further advance the Company's business strategies and research and development activities.

Comment from Mr. Yasushi Shingai

"Reborna Biosciences's goal of drug discovery for rare genetic diseases has the good potential to make a great positive impact on society. I have an experience working on innovative solutions to sociomedical issues by co-developing an anti-HIV drug with an American startup, and I am a strong believer in Reborna's mission. I decided to take on the role of advisor, not only because I have high expectations for the Company's technological capabilities, but also because I was impressed by the strong enthusiasm of President Fuji and his colleagues to help people and the world."

Comment from Koji Fuji, CEO of Reborna Biosciences, Inc.

"We are a research-based startup company specializing in the field of rare genetic diseases, aiming to contribute to the treatment of diseases with high unmet medical needs. Mr. Shingai has a brilliant track record at Japan Tobacco Inc. (JT). His achievements span a wide range of fields, from joint R&D partnerships with U.S. biotech and pharmaceutical startups to very large M&A deals in the tobacco business. Mr. Shingai's expertise is essential to the further development of our growth strategy and is expected to enhance our global competitiveness. The addition of Mr. Shingai to our team will help us continue to contribute to the healthcare industry so that innovative drugs can be delivered to patients as soon as possible."



About Mr. Yasushi Shingai

Mr. Shingai was formerly an Executive Vice President and Deputy CEO of Japan Tobacco Inc. (hereinafter “JT”) During his tenure at JT, as President of JT America Inc., Mr. Shingai established a series of partnerships with U.S. biotech start-ups and pharmaceutical companies that led to the development of an anti-HIV drug. He later served as the CFO of JT, Deputy CEO and CFO of JT International, and Representative Director, Executive Vice President and Deputy CEO of JT until his retirement in 2018. In 2007, as Deputy CEO of JT International, he successfully made an acquisition and integrated Gallaher Group Plc., a UK-based global tobacco company, by acquiring it for 2.25 trillion yen, and has a proven track record in large-scale overseas M&A. In 2011, he was appointed Representative Director and Executive Vice President of JT. He has also served as an outside director of Recruit Holdings CO., Ltd. Mr. Shingai has been serving as an outside director of Asahi Group Holdings, Inc. and Mitsubishi UFJ Financial Group, Inc. since 2018, and Dai-ichi Life Holdings, Inc. since 2019. He also focuses on supporting startup companies as an outside director of AI startups ExaWizards Inc. and Open8 Inc., and as an advisor to the venture capital firm ANRI. Mr. Shingai received a B.E. and a M.E. in Electronic Engineering from Kyoto University.

About Reborna Biosciences, Inc.

Reborna conducts drug discovery research for oral drugs that show disease modifying effects through normalizing RNA function by using small molecule drugs with high affinity for RNA. We will contribute to society by providing new treatments that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn. For more information, please visit <http://rebornabiosciences.com>.